Cyclin-Dependent Kinase Inhibitor 1B, also known as p27Kip1, is a protein encoded by the CDKN1B gene. This protein is a member of the Cip/Kip family of cyclin-dependent kinase (CDK) inhibitor proteins . The primary function of p27Kip1 is to regulate the cell cycle by inhibiting the activity of cyclin-CDK complexes, specifically cyclin E-CDK2 and cyclin D-CDK4 . By binding to these complexes, p27Kip1 prevents their activation, thereby controlling cell cycle progression at the G1 phase .
The regulation of p27Kip1 is crucial for maintaining normal cell proliferation. Extracellular growth factors that promote cell division typically reduce the transcription and translation of p27Kip1 . Additionally, increased synthesis of CDK4/6-cyclin D complexes can sequester p27Kip1, preventing it from inhibiting CDK2-cyclin E complexes . Mutations or dysregulation of the CDKN1B gene can lead to uncontrolled cellular proliferation, contributing to the development of various cancers .
Mouse anti-human antibodies are secondary antibodies produced by immunizing mice with human antigens. These antibodies are designed to specifically bind to human proteins, making them valuable tools in various research and diagnostic applications .
Secondary antibodies are often used in techniques such as ELISA, Western blotting, flow cytometry, and immunohistochemistry . They offer increased versatility and sensitivity by enabling the use of multiple detection systems (e.g., HRP, AP, fluorescence) and amplifying the signal through binding to multiple primary antibodies .
One common application of mouse anti-human antibodies is in the detection and quantification of human immunoglobulins. These antibodies can be affinity-purified and modified (e.g., through immunoaffinity chromatography, antibody fragmentation, label conjugation) to generate highly specific reagents . However, it is important to note that the use of mouse antibodies in humans can sometimes lead to the development of human anti-mouse antibodies (HAMA), which can cause allergic reactions ranging from mild rashes to severe, life-threatening responses .